Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 7/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16742593 | 0.82 | KDM4E (0.51) | PTGDR2KDM4EPKMHTTTDP1 | |
| SCHEMBL1368492 | 0.82 | ALDH1A1 (0.40) | KDM4EHTTTDP1GAAPOLB | |
| SCHEMBL1369318 | 0.81 | KDM4E (0.45) | PTGDR2KDM4EPKMHTTTDP1 | |
| SCHEMBL3710075 | 0.76 | PTGDR2 (0.49) | PTGDR2KDM4EPKMHTTTDP1 | |
| SCHEMBL16742921 | 0.76 | KDM4E (0.66) | PTGDR2KDM4EPKMHTTTDP1 | |
| SCHEMBL5532109 | 0.76 | S1PR4 (0.49) | PTGDR2KDM4EPKMHTTTDP1 | |
| SCHEMBL14764063 | 0.76 | L3MBTL1 (0.47) | HTTTDP1SMN1; SMN2L3MBTL1TSHR | |
| SCHEMBL3781153 | 0.75 | KDM4E (0.53) | PTGDR2KDM4EPKMHTTTDP1 | |
| SCHEMBL5569554 | 0.71 | S1PR4 (0.44) | PTGDR2KDM4EPKMHTTTDP1 | |
| SCHEMBL21211793 | 0.70 | KDM4E (0.58) | PTGDR2KDM4EPKMHTTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273769-B2 | Phenoxy acetic acid derivatives | MERCK SERONO SA (CH) | 2012-09-25 | — | — | US | disclosed |
| EP-2396295-A1 | PHENOXY ACETIC ACID DERIVATIVES | Merck Serono S.A. (CH) | 2011-12-21 | — | — | EP | disclosed |
| US-20110288066-A1 | PHENOXY ACETIC ACID DERIVATIVES | MERCK SERONO S.A. (CH) | 2011-11-24 | — | — | US | disclosed |
| WO-2010092043-A1 | PHENOXY ACETIC ACID DERIVATIVES | MERCK SERONO S.A. (CH) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288066-A1 | PHENOXY ACETIC ACID DERIVATIVES | HRH2, HRH1, HRH3 | PTGDR2 51/4885KDM4E 1974/4885PKM 2423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.